COAG (Hemab Therapeutics Holdings, Inc. Common Stock) Stock Analysis - News
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is a publicly traded the market company. As of May 21, 2026, COAG trades at $26.47 with a market cap of $1.27B and a P/E ratio of 0.00. COAG moved +2.40% today. Year to date, COAG is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $23.00 to $36.61. Rallies surfaces COAG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in COAG news today?
Hemab Therapeutics Secures $346.7M IPO and FDA Breakthrough for Sutacimig: Hemab Therapeutics completed an upsized IPO in May 2026, raising $346.7 million to list on Nasdaq and held $163.5 million cash at quarter end, extending runway into 2029. Sutacimig received FDA Breakthrough Therapy Designation for Glanzmann thrombasthenia, and Hemab plans to start a Phase 3 pivotal trial in H2 2026.
RA CAPITAL MANAGEMENT, L.P. bought 6.39K (~$159.04K) on May 12, 2026.
RA CAPITAL MANAGEMENT, L.P. bought 14.15K (~$346.23K) on May 11, 2026.
RA CAPITAL MANAGEMENT, L.P. bought 25.72K (~$643.00K) on May 11, 2026.
COAG Analyst Consensus
COAG analyst coverage data. Average price target: $0.00.
Common questions about COAG
What changed in COAG news today?
Hemab Therapeutics Secures $346.7M IPO and FDA Breakthrough for Sutacimig: Hemab Therapeutics completed an upsized IPO in May 2026, raising $346.7 million to list on Nasdaq and held $163.5 million cash at quarter end, extending runway into 2029. Sutacimig received FDA Breakthrough Therapy Designation for Glanzmann thrombasthenia, and Hemab plans to start a Phase 3 pivotal trial in H2 2026.
Does Rallies summarize COAG news?
Yes. Rallies summarizes COAG news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is COAG research on Rallies investment advice?
No. Rallies provides research, data, and educational context for COAG. It does not provide personalized investment advice.
